Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer.

Eun Young KimJin Gu LeeJung Mo LeeArum KimHee Chan YooKibum KimMinji LeeChulho LeeGyoonhee HanJung Min HanYoon Soo Chang

Published in: Therapeutic advances in medical oncology (2019)

BC-LI-0186 inhibits the noncanonical mTORC1-activating function of LRS. These results provide a new therapeutic strategy for NSCLC and warrant future clinical development by targeting LRS.

Keyphrases

ion batteries
small cell lung cancer
signaling pathway
solid state
current status
advanced non small cell lung cancer
brain metastases
epidermal growth factor receptor
tyrosine kinase